Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 26 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/17/2008 First Published: 8/24/2006


1.		Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 30				NCI				COG-AAML0531 AAML0531, NCT00372593

Last Modified: 10/17/2008 First Published: 8/18/2006


2.		Phase III Study of Induction Therapy Comprising Cytarabine, Daunorubicin Hydrochloride, Thioguanine, and Asparaginase Followed by Intensification Therapy Comprising Cytarabine and Etoposide in Pediatric Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 4 at diagnosis				NCI				COG-AAML0431 AAML0431, NCT00369317


3.		Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				66 and over				NCI, NHLBI				418 BMTCTN-0201, NCT00075816


4.		Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				15 to 60				Other				2006-0977 NCT00542971


5.		Phase I/II Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				60 and under				Other				UMCC 2007.055 NCT00556452


6.		Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				0 to 55				Other				8717 NCT00673114

Last Modified: 7/11/2007 First Published: 1/1/2001


7.		Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				65 and under				NCI				CPMC-IRB-AAAA5571 CPMC-CAMP-016, NCI-G00-1891, NCT00008216

Last Modified: 10/29/2007 First Published: 7/1/2002


8.		Phase II Study of Alemtuzumab, Low-Dose Total Body Irradiation, and Fludarabine Followed By HLA Class I Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Under 75				NCI				FHCRC-1591.00 NCI-H02-0089, NCT00040846

Last Modified: 2/22/2008 First Published: 7/23/2004


9.		Phase II Study of Immunosuppression Comprising Tacrolimus and Mycophenolate Mofetil for Graft-Versus-Host Disease Prevention After Nonmyeloablative Conditioning Comprising Total Body Irradiation With or Without Fludarabine and Allogeneic Stem Cell Transplantation in Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				Under 75				NCI				FHCRC-1898.00 NCT00089011

Last Modified: 6/12/2008 First Published: 2/18/2005


10.		Phase II Randomized Study of Postgrafting Immunosuppression Comprising Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus to Prevent Acute Graft-Versus-Host Disease After Unrelated Donor Filgrastim (G-CSF)-Mobilized Peripheral Blood Mononuclear Cell Transplantation With Nonmyeloablative Conditioning in Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				Any age				Other				FHCRC-1938.00 NCT00105001

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute